Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Commentary|Articles|June 17, 2026
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
Fact checked by: Gillian McGovern, Editor
Identifying high-risk patients, optimizing lipid-lowering therapy, and helping patients achieve evidence-based targets remain critical to improving cardiovascular outcomes.
Advertisement
Advertisement
Cardiovascular disease remains the leading cause of morbidity and mortality among people with diabetes. Although advances in glucose-lowering therapies have transformed diabetes management, residual cardiovascular risk remains substantial. At the 86th American Diabetes Association (ADA) Scientific Sessions, several important presentations focused on lipid management and cardiovascular prevention, highlighting both persistent treatment gaps and emerging therapies that may help further reduce cardiovascular risk.
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
Advertisement
Advertisement